Limits...
The efficacy and safety of postoperative adjuvant transarterial embolization and radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombus.

Bai T, Chen J, Xie ZB, Wu FX, Wang SD, Liu JJ, Li LQ - Onco Targets Ther (2016)

Bottom Line: In our analysis, median survival in patients with postoperative adjuvant TACE (21.91±3.60 months) or RT (14.53±1.61 months) was significantly longer than patients with hepatectomy alone (8.99±1.03 months).Also a similar result could be observed in median disease-free survival: conservative group (6.51±1.44 months), TACE group (13.98±3.38 months), and RT group (14.03±2.40 months).Postoperative adjuvant TACE and RT may be a choice for HCC patients with PVTT.

View Article: PubMed Central - PubMed

Affiliation: Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University; Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Nanning.

ABSTRACT

Objective: This study aims to find out the safety and efficiency of postoperative adjuvant transarterial chemoembolization (TACE) and radiotherapy (RT) in hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT).

Methods: From 2009 to 2010, a total of 92 HCC patients with PVTT were enrolled in this retrospective study. Patients were divided into three groups according to their adjuvant therapies (conservative group, n=51; TACE group, n=31; RT group, n=10).

Results: In our analysis, median survival in patients with postoperative adjuvant TACE (21.91±3.60 months) or RT (14.53±1.61 months) was significantly longer than patients with hepatectomy alone (8.99±1.03 months). But the difference between adjuvant TACE and RT was of no significance (P=0.716). Also a similar result could be observed in median disease-free survival: conservative group (6.51±1.44 months), TACE group (13.98±3.38 months), and RT group (14.03±2.40 months). Treatment strategies (hazard ratio [HR] =0.411, P<0.001) and PVTT type (HR =4.636, P<0.001) were the independent prognostic factors for overall survival. Similarly, the risk factors were the same when multivariate analysis was conducted in disease-free survival (treatment strategies, HR =0.423, P<0.001; PVTT type, HR =4.351, P<0.001) and recurrence (treatment strategies, HR =0.459, P=0.030; PVTT type, HR =2.908, P=0.047). Patients with PVTT type I had longer overall survival than patients with PVTT type II (median survival: 18.43±2.88 months vs 11.59±1.45 months, P=0.035).

Conclusion: Postoperative adjuvant TACE and RT may be a choice for HCC patients with PVTT.

No MeSH data available.


Related in: MedlinePlus

Kaplan–Meier curve of disease-free survival in three groups.Abbreviations: RT, radiotherapy; TACE, transarterial embolization.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4930237&req=5

f2-ott-9-3841: Kaplan–Meier curve of disease-free survival in three groups.Abbreviations: RT, radiotherapy; TACE, transarterial embolization.

Mentions: Median DFS was 6.51±1.44, 13.98±3.38, and 14.03±2.40 months for the conservative, TACE, and RT groups, respectively. Both adjuvant groups (TACE vs conservative, P=0.014; RT vs conservative, P=0.004) showed significantly longer DFS than the conservative group. However, the difference between the TACE and RT groups was not significant (P=0.078). The 6- and 12-month DFS rates were, respectively, 19.2%, and 9.9% for patients in the conservative group and 45.3% and 28.8% for patients in the TACE group. For patients in the RT group, the 6-month DFS rate was 66.7%. Data are shown in Figure 2.


The efficacy and safety of postoperative adjuvant transarterial embolization and radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombus.

Bai T, Chen J, Xie ZB, Wu FX, Wang SD, Liu JJ, Li LQ - Onco Targets Ther (2016)

Kaplan–Meier curve of disease-free survival in three groups.Abbreviations: RT, radiotherapy; TACE, transarterial embolization.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4930237&req=5

f2-ott-9-3841: Kaplan–Meier curve of disease-free survival in three groups.Abbreviations: RT, radiotherapy; TACE, transarterial embolization.
Mentions: Median DFS was 6.51±1.44, 13.98±3.38, and 14.03±2.40 months for the conservative, TACE, and RT groups, respectively. Both adjuvant groups (TACE vs conservative, P=0.014; RT vs conservative, P=0.004) showed significantly longer DFS than the conservative group. However, the difference between the TACE and RT groups was not significant (P=0.078). The 6- and 12-month DFS rates were, respectively, 19.2%, and 9.9% for patients in the conservative group and 45.3% and 28.8% for patients in the TACE group. For patients in the RT group, the 6-month DFS rate was 66.7%. Data are shown in Figure 2.

Bottom Line: In our analysis, median survival in patients with postoperative adjuvant TACE (21.91±3.60 months) or RT (14.53±1.61 months) was significantly longer than patients with hepatectomy alone (8.99±1.03 months).Also a similar result could be observed in median disease-free survival: conservative group (6.51±1.44 months), TACE group (13.98±3.38 months), and RT group (14.03±2.40 months).Postoperative adjuvant TACE and RT may be a choice for HCC patients with PVTT.

View Article: PubMed Central - PubMed

Affiliation: Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University; Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Nanning.

ABSTRACT

Objective: This study aims to find out the safety and efficiency of postoperative adjuvant transarterial chemoembolization (TACE) and radiotherapy (RT) in hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT).

Methods: From 2009 to 2010, a total of 92 HCC patients with PVTT were enrolled in this retrospective study. Patients were divided into three groups according to their adjuvant therapies (conservative group, n=51; TACE group, n=31; RT group, n=10).

Results: In our analysis, median survival in patients with postoperative adjuvant TACE (21.91±3.60 months) or RT (14.53±1.61 months) was significantly longer than patients with hepatectomy alone (8.99±1.03 months). But the difference between adjuvant TACE and RT was of no significance (P=0.716). Also a similar result could be observed in median disease-free survival: conservative group (6.51±1.44 months), TACE group (13.98±3.38 months), and RT group (14.03±2.40 months). Treatment strategies (hazard ratio [HR] =0.411, P<0.001) and PVTT type (HR =4.636, P<0.001) were the independent prognostic factors for overall survival. Similarly, the risk factors were the same when multivariate analysis was conducted in disease-free survival (treatment strategies, HR =0.423, P<0.001; PVTT type, HR =4.351, P<0.001) and recurrence (treatment strategies, HR =0.459, P=0.030; PVTT type, HR =2.908, P=0.047). Patients with PVTT type I had longer overall survival than patients with PVTT type II (median survival: 18.43±2.88 months vs 11.59±1.45 months, P=0.035).

Conclusion: Postoperative adjuvant TACE and RT may be a choice for HCC patients with PVTT.

No MeSH data available.


Related in: MedlinePlus